(Boursier.com) — Onxeo announced the extension of its portfolio of drug candidates with OX425, a new optimized compound of the OX400 series from its proprietary PlatON platform. OX425 is a new generation decoy oligonucleotide whose mechanism of action is well differentiated from that of PARP inhibitors. “Indeed, it leads to hyperactivation of PARP-1 and leads to exhaustion of the DNA damage response, inducing cancer cell death,” the company explains.
Onxeo states that in the preclinical proof-of-concept studies carried out to date, OX425 has demonstrated high antitumor activity while sparing healthy cells. “It has also shown the ability to produce multiple immunostimulatory effects, making it a promising option for potential combination with immunotherapy, especially in tumors that are not attackable by the immune system (cold tumors),” adds Onxeo.
Based on these promising results, Onxeo will finalize the preclinical development with the objective of filing an Investigational New Drug (IND) dossier with the FDA in mid-2023.
“OX425 has shown robust antitumor activity during our preclinical studies in multiple models of solid tumors of different types. OX425 is thus positioned as an innovative monotherapy and an ideal candidate for combination, in particular with immunotherapies, and specifically in the cold tumors”, concludes Dr. Shefali Agarwal, President and CEO of Onxeo.